POLBF - Poolbeg Pharma unveils new collaboration agreement
(NewsDirect)
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF)CEO Jeremy Skillington speaks to Thomas Warner from Proactive afterannouncing the pharma & biotech company has signed a newcollaboration agreement with an unspecified NASDAQ-listed biopharmacompany.
He explains that thecollaboration is aimed at developing an optimized oral drug formetabolic conditions, with Poolbeg receiving funding to produce aprototype drug encapsulating one of the partner's drugs for thesame condition.
The focus is onimproving drug delivery and achieving the ideal site of action, whichcould enhance efficacy and safety. Skillington expresses optimismabout the collaboration potentially evolving into a full licensingagreement, highlighting the goal of generating early revenues forPoolbeg. The partnership's core attraction lies in Poolbeg'svalidated encapsulation technology, which is believed to enhance thepartner's products' bioavailability and effectiveness.
The CEO emphasises the significance ofdelivering drugs to their ideal site of action, particularly formetabolic diseases. By targeting the drug orally to the preciselocation of action, it can lead to reduced dosage requirements andimproved safety. He says that Poolbeg continues to work on variousinitiatives, including the orange GLP-1 program and an oral vaccineprogram funded by the Irish government. The move towards oral deliveryaims to enhance convenience for patients and expand the company'sreach beyond traditional injectable treatments.
ContactDetails
Proactive UK Ltd
+44 20 7989 0813
Copyright (c) 2023 TheNewswire - All rights reserved.